CD44 and cancer: As HA is a targeting agent to cancer cells overexpressing CD44, HA–DPPE conjugates facilitate the recognition of modified liposomes by MiaPaCa2 cells expressing CD44, and the uptake increases with increasing molecular weight of HA from 4800 to 12,000 Da [166].